Leuprolide in Treating Adults With Hypogonadotropism

Status Completed

Clinical Trial Summary

RATIONALE: Hypogonadotropism is an abnormal condition caused by decreased production of gonadotropins, a group of hormones that stimulate the parts of the reproductive system that produce and release eggs from the ovaries or sperm from the testicles. Leuprolide may stimulate the production of gonadotropins and be effective in increasing testosterone in men and inducing ovulation in women.

PURPOSE: Clinical trial to study the effectiveness of leuprolide in treating adults who have hypogonadotropism.

Clinical Trial Description

PROTOCOL OUTLINE: Male patients receive leuprolide subcutaneously every 5 days for up to one year and are followed at weeks 4, 6, 8, and 12, then every 2 months.

Female patients receive leuprolide subcutaneously on days 1, 6, and possibly 11. Patients are followed 2 months after the last injection.

Completion date provided represents the completion date of the grant per OOPD records ;

Study Design

Primary Purpose: Treatment

Related Conditions & MeSH terms

Hypogonadism

Clinical Trial Details

NCT number	NCT00004438
Study type	Interventional
Source	FDA Office of Orphan Products Development
Contact
Status	Completed
Phase	N/A
Start date	September 1997
Completion date	September 2002

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03126656` - Effects of Testosterone on Myocardial Repolarization	Phase 4
Terminated	`NCT02419105` - Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors	Phase 3
Withdrawn	`NCT02137265` - Assessing the Efficacy of Clomiphene Citrate in Patients With Azoospermia and Hypoandrogenism	N/A
Completed	`NCT02222558` - Oral Testosterone for the Treatment of Hypogonadism in Males	Phase 2
Completed	`NCT02233751` - Pharmacokinetic Study of Subcutaneous Testosterone Enanthate	Phase 1
Completed	`NCT01887418` - Pharmacokinetic Study of Testosterone Enanthate	Phase 1/Phase 2
Terminated	`NCT01092858` - NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)	Phase 4
Completed	`NCT00624624` - Follow-up of Serum Androgen Profile After Bariatric Surgery in Men With Obesity Related Hypogonadotropic Hypogonadism	N/A
Completed	`NCT00752869` - Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement	Phase 4
Completed	`NCT00613288` - Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism	N/A
Completed	`NCT00119483` - Older Men and Testosterone	N/A
Completed	`NCT00838838` - Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis	N/A
Withdrawn	`NCT00398034` - Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-treated Chronic Pain Patients: A Pilot Study.	Phase 2
Completed	`NCT02921386` - The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate	Phase 2
Completed	`NCT02937740` - Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™	Phase 4
Completed	`NCT01717768` - Oral Testosterone for the Treatment of Hypogonadism	Phase 2
Terminated	`NCT01460654` - Testosterone and Alendronate in Hypogonadal Men	Phase 2
Completed	`NCT00998933` - Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure	Phase 1
Withdrawn	`NCT00710827` - Nebido Versus Placebo in Elderly Men With Typical Symptoms of Late Onset Hypogonadism Over a Period of 54 Weeks	Phase 4
Completed	`NCT00663793` - ORAL T-6: Oral Androgens in Man-6	Phase 1